Chronic inflammation is a harmful process that can lead to fibrosis, organ damage, and even loss of organ function. It occurs when the immune system is activated and remains active for a prolonged period of time. Research has shown that targeting of Cannabinoid Type II receptors on immune cells can reduce inflammation and limit fibrosis.
Lenabasum is a small molecule that selectively activates CB2 receptors. Taken orally, this novel drug activates the resolution of inflammation and limits fibrosis, without suppressing the immune system.